Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich
Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )
21 Oct 2025

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA
ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer ( Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA )
20 Oct 2025

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer ( Prof Andrea Necchi -  The Vita-Salute San Raffaele University, Milan, Italy )
20 Oct 2025

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

ESMO 2025: Renal highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Renal highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Oct 2025

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )
20 Oct 2025

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
20 Oct 2025

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )
20 Oct 2025

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Dr Janice Mehnert - NYU Langone Health, New York, USA
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival ( Dr Janice Mehnert - NYU Langone Health, New York, USA )
20 Oct 2025

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark
IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma ( Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark )
20 Oct 2025

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA
Zanzalintinib plus atezolizumab improves survival in refractory mCRC ( Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA )
20 Oct 2025